Copyright
©The Author(s) 2019.
World J Clin Cases. Aug 6, 2019; 7(15): 1964-1977
Published online Aug 6, 2019. doi: 10.12998/wjcc.v7.i15.1964
Published online Aug 6, 2019. doi: 10.12998/wjcc.v7.i15.1964
Figure 3 Clinical response for patients with or without intratumoral human epidermal growth factor receptor 2 heterogeneity.
Tumor shrinkage (left) and clinical response (right) was evaluated by RECIST ver. 1.1 for 58 patients who have measurable metastatic lesions. ORR was 79.5% in the Homo group, which was significantly higher than that in the Hetero group (35.7%, P = 0.002). CR: Complete response; PR: Partial response; SD: Stable disease; PD: Progressive disease; ORR: Overall response rate (CR plus PR).
- Citation: Kaito A, Kuwata T, Tokunaga M, Shitara K, Sato R, Akimoto T, Kinoshita T. HER2 heterogeneity is a poor prognosticator for HER2-positive gastric cancer. World J Clin Cases 2019; 7(15): 1964-1977
- URL: https://www.wjgnet.com/2307-8960/full/v7/i15/1964.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v7.i15.1964